問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3138Cases

2018-07-24 - 2021-03-17

Phase III

A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Sotagliflozin

Participate Sites
8Sites

Terminated8Sites

江晨恩
Taipei Veterans General Hospital

2017-11-15 - 2022-12-31

Phase III

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

  • Condition/Disease

    Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

  • Test Drug

    Sotagliflozin

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated7Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2016-09-01 - 2018-03-31

Phase III

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia

  • Condition/Disease

    Community-Acquired Bacterial Pneumonia

  • Test Drug

    BC-3781 tablet

Participate Sites
7Sites

Terminated5Sites

2016-04-29 - 2019-04-28

Phase I

A MULTIPLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE AND MULTIPLE-ASCENDING DOSE, ADAPTIVE PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7020322 FOLLOWING ORAL ADMINISTRATION IN HEALTHY SUBJECTS AND CHRONIC HEPATITIS B PATIENTS

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    RO7020322

Participate Sites
5Sites

Terminated4Sites

2015-11-01 - 2019-12-31

Phase III

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Bexagliflozin Tablets

Participate Sites
9Sites

Terminated7Sites

江晨恩
Taipei Veterans General Hospital

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2015-10-01 - 2019-05-15

Phase III

An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures

  • Condition/Disease

    Symptomatic peripheral artery disease

  • Test Drug

    Xarelto tablet

Participate Sites
8Sites

Terminated7Sites

林宗憲
Kaohsiung Municipal Gangshan Hospital

未分科

江晨恩
Taipei Veterans General Hospital

2015-08-01 - 2018-12-31

Phase II

Antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan, assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according to a specific genetic profile.

  • Condition/Disease

    hypertension

  • Test Drug

    Rostafuroxin

Participate Sites
14Sites

Terminated12Sites

2014-06-01 - 2018-08-09

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-10-09 - 2018-12-31

Phase III

Confirmatory Study of DSP-5423P in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    Schizophrenia

  • Test Drug

    DSP-5423P

Participate Sites
6Sites

Terminated6Sites

黃宗正
National Taiwan University Hospital

2009-01-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 214 215 216 217 218 314
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB